Israeli Biotech Silaxion Reveals SIL204 May Boost Immune System to Target Tumors

Israeli biotechnology company Silaxion Therapeutics (Nasdaq: SLXN) announced new preclinical findings indicating that its leading treatment candidate, SIL204, could enhance the immune system's ability to recognize and attack tumors. SIL204 is designed to silence the mutant KRAS gene, a key driver in about 90% of pancreatic cancers and 30-35% of non-small cell lung cancers (NSCLC), using RNA interference technology.

Beyond directly targeting KRAS, the new data show SIL204 influences tumor-immune interactions by acting on three immune pathways. It increases MHC-I expression, helping cancer cells present antigens to the immune system, raises FAS receptor levels which may reactivate programmed cell death in tumor cells, and reduces HLA-G expression, a molecule tumors use to evade immune responses.

These mechanisms suggest SIL204 could simultaneously help the immune system detect tumors, increase their vulnerability to immune attack, and diminish their immune evasion strategies. This is particularly significant for pancreatic cancer, where immune checkpoint inhibitors like anti-PD-1 or anti-PD-L1 therapies have limited effectiveness due to the tumors often being immunologically "cold" and difficult for the immune system to penetrate.

Silaxion's findings support the potential of combining SIL204 with immunotherapies to improve treatment outcomes. However, the company emphasizes that these results are preclinical, and further studies are needed to confirm clinical benefits in patients.

The research advances the scientific rationale for testing SIL204 in combination with immune checkpoint inhibitors, aiming to make resistant tumors more responsive to immunotherapy.